COPPINI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.324
EU - Europa 7.765
AS - Asia 4.555
SA - Sud America 659
Continente sconosciuto - Info sul continente non disponibili 212
AF - Africa 115
OC - Oceania 62
Totale 22.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.117
PL - Polonia 2.151
RU - Federazione Russa 1.971
IT - Italia 1.779
SG - Singapore 1.259
CN - Cina 1.157
HK - Hong Kong 621
BR - Brasile 516
VN - Vietnam 512
IE - Irlanda 414
KR - Corea 334
SE - Svezia 302
DE - Germania 233
FR - Francia 215
FI - Finlandia 165
GB - Regno Unito 151
IN - India 141
CA - Canada 127
BD - Bangladesh 106
JO - Giordania 103
CH - Svizzera 90
ID - Indonesia 90
UA - Ucraina 66
JP - Giappone 60
AU - Australia 59
AR - Argentina 57
TR - Turchia 54
NL - Olanda 52
ES - Italia 41
MX - Messico 40
BE - Belgio 38
ZA - Sudafrica 30
IQ - Iraq 23
EC - Ecuador 21
CI - Costa d'Avorio 19
GR - Grecia 18
VE - Venezuela 16
NG - Nigeria 15
CL - Cile 14
PK - Pakistan 14
AT - Austria 12
MA - Marocco 12
LT - Lituania 11
CO - Colombia 9
KE - Kenya 9
PH - Filippine 9
RO - Romania 9
PY - Paraguay 8
UZ - Uzbekistan 8
DZ - Algeria 7
EG - Egitto 7
KZ - Kazakistan 7
PE - Perù 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
MY - Malesia 6
NP - Nepal 6
SA - Arabia Saudita 6
CR - Costa Rica 5
HN - Honduras 5
HU - Ungheria 5
KW - Kuwait 5
AL - Albania 4
BJ - Benin 4
DK - Danimarca 4
GE - Georgia 4
IL - Israele 4
NO - Norvegia 4
UY - Uruguay 4
AZ - Azerbaigian 3
BB - Barbados 3
BO - Bolivia 3
BY - Bielorussia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
GT - Guatemala 2
GY - Guiana 2
IR - Iran 2
KG - Kirghizistan 2
MK - Macedonia 2
MU - Mauritius 2
PR - Porto Rico 2
SR - Suriname 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
Totale 22.457
Salva come PNG Salva come JPEG
Città #
Warsaw 2.141
Santa Clara 1.725
Ashburn 1.270
Singapore 897
Fairfield 742
Hong Kong 541
Dublin 404
Chandler 369
Woodbridge 343
San Jose 342
Seoul 330
Seattle 320
Florence 301
Cambridge 299
Milan 276
Houston 268
Beijing 264
Wilmington 245
Hefei 226
Ann Arbor 217
Ho Chi Minh City 155
Rome 140
Council Bluffs 136
Los Angeles 133
Dallas 130
Buffalo 129
Lawrence 128
Altamura 124
Munich 124
The Dalles 109
Lauterbourg 106
New York 103
Hanoi 102
Princeton 99
Bern 83
Moscow 78
Mumbai 74
Jakarta 68
Boston 65
Helsinki 64
Shanghai 63
San Diego 59
Dong Ket 57
Medford 57
São Paulo 53
Tokyo 53
Melbourne 48
Boardman 46
Kent 46
Bologna 43
Turku 43
Clifton 41
Montreal 36
Brussels 35
Falls Church 35
Naples 35
Orem 35
Frankfurt am Main 33
Paris 32
London 30
Barcelona 27
Chicago 27
Istanbul 26
Toronto 26
Figino 25
Phoenix 24
Redondo Beach 24
Norwalk 23
Rio de Janeiro 23
Turin 22
Lappeenranta 21
Abidjan 19
Guangzhou 19
Da Nang 18
Dearborn 18
Andover 17
Johannesburg 17
Palermo 17
Redwood City 17
Scandicci 17
Atlanta 16
Denver 15
Mexico City 15
Abuja 14
Bengaluru 14
Chennai 14
Falkenstein 14
Poplar 14
Amsterdam 13
Miano 13
Nanjing 13
Haiphong 12
Tianjin 12
Brasília 11
Brooklyn 11
Hillsboro 11
Mudanya 11
Nuremberg 11
Washington 11
Yubileyny 11
Totale 15.233
Salva come PNG Salva come JPEG
Nome #
Ipertensione arteriosa LINEE GUIDA REGIONE TOSCANA 588
"Tuscany Registry for sAdden Cardiac DEath": metodo per la creazione di un registro multicentrico per la gestione di eventi di morte improvvisa in età giovanile 491
Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy. 438
Atrial Remodeling in Hypertrophic Cardiomyopathy 407
Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. 378
Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: A comparison of the cardiac troponin T E163R and R92Q mouse models 352
Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment 327
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience 316
Oleuropein aglycone protects against MAO-A-induced autophagy impairment and cardiomyocyte death through activation of TFEB. 315
Myocardial Dysfunction in Hypertrophic Cardiomyopathy: Primary Effects of Sarcomeric Mutations Versus Secondary EC-Coupling Remodelling 305
Late sodium current inhibitors to treat exercise induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. 299
Electrical defects of the transverse-axial tubular system in cardiac diseases 287
Optical investigation of action potential and calcium handling maturation of hiPSC-cardiomyocytes on biomimetic substrates 283
Altered Ca2+ and Na+ homeostasis in human hypertrophic cardiomyopathy: Implications for arrhythmogenesis 281
T-Tubular Electrical Defects Contribute to Blunted β-Adrenergic Response in Heart Failure. 280
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 274
Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy 266
Quantitative assessment of passive electrical properties of the cardiac T-tubular system by FRAP microscopy 265
A Novel Method of Isolating Myofibrils From Primary Cardiomyocyte Culture Suitable for Myofibril Mechanical Study 263
Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: a Translational Study 249
Design of muscle contraction assist devices by liquid crystalline elastomers 247
Liquid Crystalline Networks toward Regenerative Medicine and Tissue Repair 244
Development of Light-Responsive Liquid Crystalline Elastomers to Assist Cardiac Contraction 236
Action potential propagation in transverse-axial tubular system is impaired in heart failure 231
Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy 230
Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain 228
Real-time optical manipulation of cardiac conduction in intact hearts 228
Arrhythmia susceptibility in a rat model of acute atrial dilation 226
SODIUM-DEPENDENT GLUCOSE TRANSPORTERS (SGLT) IN HUMAN ISCHEMIC HEART: A NEW POTENTIAL PHARMACOLOGICAL TARGET 223
Calcium handling maturation and adaptation to increased substrate stiffness in human iPSC-derived cardiomyocytes: The impact of full-length dystrophin deficiency 213
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 211
Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy 209
Impact of Mavacamten on Force Generation in Single Myofibrils from Rabbit Psoas and Human Cardiac Muscle 205
Chronic Atrial Fibrillation Alters the Functional Properties of Ifin the Human Atrium 203
Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2 202
UDP-glucose enhances outward K+currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors 201
Impact of detubulation on force and kinetics of cardiac muscle contraction 200
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 199
Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy 199
Representativeness of the "Fiesole Misurata" study database for use in pharmaco-epidemiological investigations on adherence to antihypertensive medications 197
The transverse-axial tubular system of cardiomyocytes. 196
Functional cardiac imaging by random access microscopy 195
Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM 193
[Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling] 193
Late Sodium Current Inhibition Reverses Electro-Mechanical Dysfunction in Human Hypertrophic Cardiomyopathy 191
Pharmacological inhibition of serine proteases to reduce cardiac inflammation and fibrosis in atrial fibrillation 189
Optical clearing in cardiac imaging: A comparative study 189
BPS2025 - Long-term effect of Mavacamten impact force and sarcomere density in a MYBPC3 iPSC-cardiomyocyte model of hypertrophic cardiomyopathy 188
[Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018] 188
Optogenetic manipulation of cardiac electrical dynamics using sub-threshold illumination: dissecting the role of cardiac alternans in terminating rapid rhythms 187
Whole heart cytoarchitecture at micron-scale resolution 187
Design of Biocompatible Liquid Cristal Elastomers Reproducing the Mechanical Properties of Human Cardiac Muscle 187
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 186
R4496C RyR2 mutation impairs atrial and ventricular contractility 185
Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial 185
Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials 184
Genetic characterization of juvenile sudden cardiac arrest and death in Tuscany: The ToRSADE registry 181
Time resolved depression of isometric force by Mavacamten in single myofibrils from rabbit psoas and human cardiac muscle 181
Efficacy and safety of dysopiramide in patients with obstructive hypertrophic cardiomyopathy 177
Reply to entcheva: The impact of T-tubules on action potential propagation in cardiac tissue 175
Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study 174
Optogenetic confirmation of transverse‐tubular membrane excitability in intact cardiac myocytes 173
Mavacamten depresses human atrial contractility in the same EC50% range as human ventricle 172
Defects in T-tubular electrical activity underlie local alterations of calcium release in heart failure 171
Paradoxical prolongation of QT interval during exercise in patients with hypertrophic cardiomyopathy: cellular mechanisms and implications for diastolic function 168
Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex 166
Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials 166
Cardiomyocyte-specific Gq signalling and arrhythmias: Novel insights from DREADD technology 165
Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations 165
Contraction and electrophysiological abnormalities in myofilament mutation-positive and mutation-negative human HCM myocardium 164
Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy 164
Altered calcium regulation in isolated cardiomyocytes from Egr-1 knock-out mice 163
Impact of RyR2 mutation responsible for Cathecolaminergic Polymorphic Ventricular Tachycardia (CPTV) on the short term interval-force relationship of atrial and ventricular myocardium 162
Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models 161
Sex-Specific Classification of Drug-Induced Torsade de Pointes Susceptibility Using Cardiac Simulations and Machine Learning 160
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 155
Response to Letter Regarding Article, "Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy" 155
Structural Mapping of Action Potential Propagation Pathways through Healthy and Diseased Heart 155
Isolation and functional characterization of human ventricular cardiomyocytes from fresh surgical samples. 154
Cellular determinants of arrhythmic rysk in hypertrophic cardiomyopathy 154
Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives 153
Impact of R4496C RyR2 mutation on myocardial contractility 152
Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy 149
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside 149
Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy 148
1473Microvascular coronary disease and myocardial fibrosis within the spectrum of hypertrophic cardiomyopathy: a histopathologic study 148
Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. 147
Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle 147
Electrophysiological and molecular remodeling in septal myocytes from fHCM patients 146
Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018 Abstracts 145
Neural Effects on Cardiac Electrophysiology 145
Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy 144
Targets for therapy in sarcomeric cardiomyopathies. 143
Clinical research in neonates and infants: Challenges and perspectives 140
T-tubule remodeling in human hypertrophic cardiomyopathy 137
Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy 136
Electrophysiological mechanisms underlying T wave pseudonormalisation on stress ECGs in hypertrophic cardiomyopathy 133
Letter to the Editor 133
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium 133
Transthyretin aggregates affect viability and functional properties of cardiomyocytes. 130
Totale 20.858
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.472
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.472
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022849 0 49 78 41 50 51 51 46 49 65 149 220
2022/20231.973 165 364 102 116 122 306 234 104 268 27 63 102
2023/2024885 37 91 111 37 52 127 51 179 17 54 50 79
2024/20255.732 237 658 376 805 1.465 694 132 385 294 138 242 306
2025/20267.556 715 958 667 819 826 267 765 387 527 482 275 868
2026/2027255 253 2 0 0 0 0 0 0 0 0 0 0
Totale 22.692